کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3201465 | 1201956 | 2008 | 5 صفحه PDF | دانلود رایگان |
BackgroundThe efficacy of the intranasal corticosteroid mometasone furoate nasal spray (MFNS) for treatment of nasal polyposis was demonstrated in 2 large clinical trials.ObjectiveTo evaluate the onset of MFNS symptomatic effect, data from the 2 trials were pooled and analyzed to determine the first day subjects experienced significant symptom relief.MethodsSubjects with nasal polyposis randomized to MFNS 200 μg twice daily or placebo scored symptoms on a 3-point scale (0 = none; 3 = severe) and measured peak nasal inspiratory flow immediately before the morning dose. Onset of symptomatic effect was defined as the first day a statistically significant (P < .05) lasting response was observed for MFNS compared with placebo.ResultsA total of 447 subjects with bilateral nasal polyps and clinically significant nasal congestion/obstruction were analyzed. Compared with placebo, MFNS 200 μg twice daily demonstrated statistically significant (P < .05) relief of anterior rhinorrhea by day 2 (–10.9% vs +5.7%), nasal congestion by day 3 (–15.1% vs –7.6%), postnasal drip by day 5 (+1.1% vs +4.6%), and sense of smell by day 13 (–9.6% vs –5.6%). Significant improvement in peak nasal inspiratory flow was seen by day 2 (increase of 6.22 L/min vs 1.48 L/min for placebo; P = .03).ConclusionMometasone furoate nasal spray 200 μg twice daily rapidly improves the symptoms of nasal polyposis, leading to lasting relief of most major symptoms within 2 (24 hours after the first dose) to 5 days of initiating therapy.
Journal: Journal of Allergy and Clinical Immunology - Volume 121, Issue 4, April 2008, Pages 928–932